Masera G, Uderzo C, Corbella E, Carnelli V
Acta Haematol. 1978;59(4):205-14. doi: 10.1159/000207763.
13 children affected by acute lymphoblastic leukemia in advanced stage of illness received a sequential therapy with daunorubicin and L-asparaginase. During daunorubicin therapy a significant decrease of bone hypercellularity as well as circulating cells occurred, a further cycle with a scarcely myelotoxic drug, L-asparaginase, was administered: a 10/13 (76.9%) remission of the disease was then achieved. This therapeutic trial was well accepted and could be more extensively used in the patients in relapse. A remission lasting between 4 and 28 weeks was observed.
13名处于疾病晚期的急性淋巴细胞白血病患儿接受了柔红霉素和L-天冬酰胺酶的序贯治疗。在柔红霉素治疗期间，骨髓细胞增多以及循环细胞显著减少，随后给予一个几乎没有骨髓毒性的药物L-天冬酰胺酶的进一步疗程：疾病缓解率达10/13（76.9%）。该治疗试验被广泛接受，可更广泛地用于复发患者。观察到缓解期持续4至28周。
